Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has issued an announcement.
Fusen Pharmaceutical has issued a supplemental announcement detailing the circumstances behind its recent change of auditor, following the resignation of KPMG over a dispute on the audit fee for the 2025 financial year. After KPMG proposed a substantial fee increase that management repeatedly rejected, the board, on the recommendation of the audit committee, appointed CCTH as the new auditor to fill the vacancy until the next annual general meeting.
The company laid out a detailed timeline from mid‑2025 discussions to December negotiations, highlighting that KPMG confirmed there were no unresolved audit issues or disagreements beyond the audit fee. Management had simultaneously solicited proposals from three audit firms to safeguard timely completion of the 2025 audit, indicating an effort to maintain reporting continuity and reassure shareholders and potential investors about the integrity and independence of the audit process.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.72 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited is a Hong Kong–listed pharmaceutical group incorporated in the Cayman Islands and traded under stock code 1652. The company operates through its subsidiaries, focusing on the development, manufacturing and sale of pharmaceutical products for the healthcare market and investors in Greater China and beyond.
Average Trading Volume: 605,070
Technical Sentiment Signal: Buy
Current Market Cap: HK$948.4M
For a thorough assessment of 1652 stock, go to TipRanks’ Stock Analysis page.